الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 91 |  |  |
| | | from | 91 | | |
Abstract
A prospective descriptive cross-sectional study of 300 patients with chronic hepatitis C virus infection based on Fib-4,laboratory data and ultrasongraphy non-cirrhotic patients were 30.3% ,while 70.7% were cirrhotic with Child A 66% and Child B were 34%. which were treated by Direct Acting Antivirals. All patients were treated according to Egyptian treatment protocol for treatment of chronic hepatitis C virus infected patients by one of the following regimens sofosbuvir and simeprevir regimen by 21%, sofosbuvir and daclatasvir regimen by 46%, sofosbuvir, daclatasvir and ribavirin regimen by 29.7%, sofosbuvir, daclatasvir, ribavirin and ombitasvir, paritaprevir and ritonavir regimen by 0.7 %, sofosbuvir and ledipasvir regimen by 0.3% and finaly ombitasvir,paritaprevir and ritonavir plus ribavirin regimen by 2%, for 12 weeks with follow up every 4 weeks for assessment of drugs side effects .
Almost all Patients included in study were naïve who were first time to receive antiviral treatment for hepatitis C virus by 99.67 % and only 0.3% were relapse after treatment by Interferon and ribavirin regimen for 48 weeks. All patients were subjected to thorough clinical examination and laboratory investigation to detect side effects of this regimens after 4 weeks , 8 weeks and 12 weeks after starting treatment.
Clinical side effects were detected in the form of headache and dizziness. Gastrointestinal tract manifestations in a form of nausea and vomiting abdominal pain and diarrhea General constitutional clinical side effects were in a form of general malaise and fatigue. Chest manifestations were in a form of cough and dyspnea. Skin manifestations were in the form of itching , eczema and hair loss. Musculoskeletal system was in a form of musculoskeletal pain. Results showed that majority of patient had neither clinical nor laboratory side effects after receiving treatment. Main side effects reported by sofosbuvir and simeprevir regimen group were neurological manifestations (pvalue=0.19), sofosbuvir and daclatasvir regimen group were also neurological manifestations (pvalue=0.19), sofosbuvir, daclatasvir and ribavirin regimen group were gasterointestinal manifestations (pvalue=0.340) and in ombitasvir,paritaprevir and ritonavir regimen group of patients reported neurological manifestations (pvalue=0.19).
In all the treatment regimens and along the study course no serious side effects were reported especially hepatic decompensation. No side effect that lead to treatment discontinuation, no reported death cases and during the follow up HCC was not reported.